Another study, the
NSABP B-32 phase-III trial, observed false negative rate of 9.8%, with 8.9% for T2 tumours and 10.3% for T1 tumours, and an accuracy of 97.3%5.
Dual blockade of HER2 with trastuzumab and lapatinib has been examined in the neoadjuvant treatment setting in 4 randomized studies (Table 1), comparing the activity of trastuzumab, lapatinib, or both with paclitaxel: the phase III NeoALTTO [81], the phase II CHER-LOB [82], the phase III
NSABP B-41 [83], and the phase III CALGB 40601 [84].
(23.) Fisher ER, Dignam J, Tan-Chiu E, et al, for the National Surgical Adjuvant Breast Bowel Project (
NSABP) Collaborating Investigators (1999), Pathologic findings from the National Surgical Adjuvant Breast Project (
NSABP) eight-year update of Protocol B-17.
Julian et al., "Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (
NSABP B-35): a randomised, double-blind, phase 3 clinical trial," The Lancet, vol.
Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the
NSABP B-32 randomised phase III trial.
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum:
NSABP R-03.
pCR (Pathologic complete response) is the best indicator of efficacy of NACT which eventually also is predictor of DFS(Disease free survival) & OAS(Ovearall survival) as seen in trials like
NSABP 18& 27.
Adding oxaliplatin to either regimen increases toxicity and does not improve efficacy, judging from results of the National Surgical Adjuvant Breast and Bowel Project (
NSABP) protocol RO4 trial that were reported at the annual Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology.
According to the National Surgical Adjuvant Breast Project (
NSABP) B17 protocol, 80% of DCIS cases were nonpalpable (13).
Study Control Trastuzumab Reduction in DFS arm arm relative risk hazard of recurrence ratio
NSABP B-31 AC [right AC [right arrow] T arrow] TH Joint analysis 0.48 (N = 2700) NCCTG 52% N9831 AC [right AC [right arrow] T arrow] TH (N = 3300) HERA Any Trastuzumab (N = 5090) 1 year 46% 0.54 BCIRG 006 AC [right AC [right 40% 0.49 arrow] D arrow] DH 33% 0.61 (N = 3150) DCH FINHer D [right DH [right arrow] FEC arrow] FEC (N = 232) V [right VH [right 0.42 arrow] FEC arrow] FEC
NSABP, National Surgical Adjuvant Breast and Bowel Project; NCCTG, North Central Cancer Treatment Group; HERA, Herceptin Adjuvant Trial; BCIRG, Breast Cancer International Research Group; FINHer, Finland Herceptin Study.
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The
NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.